Spotlight on the Rare & Challenging EGFR Exon 20 Insertion in NSCLC

Guest: S. Michelle Shiller, DO, AP/CP, MGP <br> Guest: John V. Heymach, MD, PhD <br> <p>Exon 20 insertion mutations account for up to 10 percent of <em>EGFR </em>mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, <em>EGFR </em>mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.</p> <p style="text-align: right;">All trademarks are the property of their respective owners.<br /><span>©</span>2021 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved.<br />December, 2021. VV-MEDMAT-56973</p>